U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment.
Susan M GrahamDouglas BartholdBrett HauberAaron T BrahEnrique SaldarriagaAnn C CollierRodney J Y Honull nullMahomed-Yunus MoosaJane M SimoniPublished in: Journal of the International AIDS Society (2023)
PWH in the United States may soon have several options for LA-ART. Our results suggest that LA oral tablets will be preferred by many patients over their current daily oral treatment, while implants and injections with longer duration may be acceptable to some. Future research should investigate sources of preference heterogeneity and actual uptake of and adherence to LA-ART products, when available.
Keyphrases
- antiretroviral therapy
- hiv infected
- end stage renal disease
- human immunodeficiency virus
- newly diagnosed
- chronic kidney disease
- ejection fraction
- hepatitis c virus
- hiv positive
- single cell
- type diabetes
- physical activity
- combination therapy
- peritoneal dialysis
- patient reported outcomes
- drinking water
- current status
- south africa
- men who have sex with men
- smoking cessation
- soft tissue
- glycemic control